Rafferty Asset Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $725K | Sell |
|
|||||
|
2025
Q1 | $564K | Buy |
|
|||||
|
2024
Q4 | $725K | Buy |
|
|||||
|
2024
Q3 | $2.39M | Sell |
|
|||||
|
2024
Q2 | $2.63M | Sell |
|
|||||
|
2024
Q1 | $7.91M | Buy |
|
|||||
|
2023
Q4 | $2.6M | Buy |
|
|||||
|
2023
Q3 | $1.86M | Sell |
|
|||||
|
2023
Q2 | $2.82M | Buy |
|
|||||
|
2023
Q1 | $2.69M | Sell |
|
|||||
|
2022
Q4 | $3.16M | Buy |
|
|||||
|
2022
Q3 | $2.16M | Buy |
|
|||||
|
2022
Q2 | $1.03M | Buy |
|
|||||
|
2022
Q1 | $1.86M | Sell |
|
|||||
|
2021
Q4 | $2.15M | Buy |
|
|||||
|
2021
Q3 | $963K | Sell |
|
|||||
|
2021
Q2 | $1.08M | Sell |
|
|||||
|
2021
Q1 | $2.1M | Buy |
|
|||||
|
2020
Q4 | $217K | Buy |
|